Mental Health Watchdog Exposes Dangerous Psychiatric Drug Use
CLEARWATER, Fla., April 13, 2017 (GLOBE NEWSWIRE) — Over 2000 people from Italy, France, Switzerland, Germany, Netherlands and Denmark marched in the streets of Florence, Italy last weekend to protest the increasing number of Europeans, especially children, being prescribed dangerous psychotropic drugs. The Italian chapter of the international mental health watchdog group, Citizens Commission on Human Rights (CCHR) organized the march, in coordination with other chapters including CCHR Florida and all across the US. They pointed out that more than 33 percent of Europeans aged 18–29 have taken such drugs. CCHR was established by the Church of Scientology and renown psychiatrist, Dr. Thomas Szasz in 1969.
The march coincided with a European Psychiatric Association (EPA) Congress being held in Florence, with CCHR saying the conference promotes drug and other psychiatric interventions that puts Italians and other Europeans’ mental health and lives at risk.
Among speakers at the rally was Prof. Vincenza Palmieri, founder of the “Living without Psychiatric Drug” program: “For 30 years I have been seeing families and individuals being trapped in a system that sucks their lives away with the use of mind-altering drugs. We must spread information, knowledge and courage,” to oppose this, he said.
The march was followed by the opening of a world-acclaimed exhibition on psychiatry at the Auditorium del Duomo (via de’ Cerretani 54r – Florence). Called “PSYCHIATRY: SOCIAL CONTROL AND VIOLATIONS OF HUMAN RIGHTS,” it documents the harmful history of psychiatry and its contemporary abuses. This includes Italy being the birthplace of electroshock treatment that the protestors say should be banned. More than 90 clinics in Italy still administer electroshock treatment, which was invented by Italian psychiatrist Ugo Cerletii in 1938. The exhibition is open until April 10 at Auditorium del Duomo, via de’ Cerretani 54r, with free entrance from 10:00 till 19:00.
Prof. Palmieri; Mr. Francesco Miraglia, a lawyer often engaged in defending human rights; and Mrs. Serena Perini, Councilwoman and President of the Florence Town Hall’s Committee on Peace, Human Rights, Solidarity, International Relations, Immigration and Equal Opportunities, thanked CCHR for the extensive information in the exhibit. The consensus was that without the exhibit, many mental health abuses would have remained unknown.
The worldwide concern about increasing psychotropic drug use is prompted by the drugs’ now well documented adverse effects, including suicidal and homicidal thoughts, psychosis, mania, aggression, hallucinations, severe liver damage, birth defects, diabetes, heart attack, stroke and sudden death.
for more information please click on Mental Health Watchdog Exposes Dangerous Psychiatric Drug Use
Report: More drug innovation necessary for mental health
As the healthcare industry looks to make good on a promise of patient-centricity, advocacy groups and regulators have increased their focus on earlier patient involvement in clinical trials, with particular attention on so-called patient-reported outcome (PRO) measures. However, according to new research looking at payer perspectives on mental health, use of PROs that track patients’ wishes and experiences in their own voices, unamended by clinicians, may not help manufacturers make a more persuasive case about a new drug when talking to insurers. The research, released by inVentiv Health, found that 92% of private payers do not wish to see wider use of such measures in clinical trials.
In addition to harboring reservations about PROs that capture the patient’s unfiltered point of view, many payers express skepticism when it comes to health economics and outcomes research (HEOR) that is carried out by or paid for exclusively by the drug’s manufacturer. Sixty-nine percent of payers interviewed would not place much stock in HEOR generated solely by a product marketer without corroboration by an impartial organization or institution.
The data come from inVentiv Health research conducted on the U.S. payer perspective from November 2016 through January 2017. This research draws on extensive interviews with executives who are responsible for reimbursement and formulary decisions about regional and national health plans representing more than 59 million lives. The research results are described in a white paper titled, “Mental Health: An Insurance Industry Perspective.”
The white paper is a follow-up to “An Advocacy Rx for Progress in Mental Health,” a report based on in-depth interviews with advocacy and mental health experts across Europe and the U.S. aimed at better understanding the barriers to advancements in the field of mental health. When asked to describe their top priorities, many advocacy groups said they would like their pharmaceutical partners to develop more advanced screens and assays for early detection and diagnosis of mental health conditions.
for more information please click on Report: More drug innovation necessary for mental health